Vaxxas sign deal with Queensland State Government
As published by 7 News, Vaxxas has signed an agreement with the Queensland government¬†to produce enough needle-free vaccine kits to deliver 300 million doses each year.
Vaxxas agreed to produce its high-density micro Array Patch vaccine delivery system in Queensland after the Palaszczuk government committed to building a new medical plant in Brisbane. Treasurer Cameron Dick said the Vaxxas system had the potential to “revolutionise the delivery of vaccines around the world”.
Vaxxas is a biotechnology company pioneering the next generation of needlefree vaccine delivery platforms with its Nanopatch.
The company’s technology features thousands of micron-sized pointed tips, or projections, which help to deliver vaccines directly to the abundant immune cells found just below the surface of the skin.
Using the Nanopatch, the vaccination process is simple and safe, patient friendly, requires less vaccine than traditional injections into the muscle, and no refrigeration is required – this enables vaccines to be administered in areas that had previously been hard to reach.
The company formed in 2011 and has been harnessing the NCRIS-funded networks of ANFF and Microscopy Australia ever since.
On the announcement, Dr Ian Griffiths, ANFF CEO, said: ‚ÄúWe at ANFF are especially proud that the Vaxxas technology is now moving into manufacturing here in Australia, as it was born of ANFF equipment and engineering. This is an excellent demonstration of how ANFF has, and will continue to support the rebooting of the Australian economy. We believe this is one of the many ANFF enabled technologies that will start to form a new era of advanced manufacturing in Australia.
‚ÄúCongratulations to Vaxxas, and to all of those involved in taking what started as outstanding fundamental research, and has been pulled through to become a fantastic platform that will soon be changing lives and creating new jobs.‚Äù
Read more about ANFF’s involvement in Vaxxas’ technology platform by clicking here.
Find out more about Vaxxas here.